B-intervention	0	8	Visceral
I-intervention	9	20	osteopathic
I-intervention	21	33	manipulative
I-intervention	34	43	treatment
O	44	51	reduces
O	52	59	patient
O	60	68	reported
B-condition	69	78	digestive
I-condition	79	89	toxicities
O	90	97	induced
O	98	100	by
O	101	109	adjuvant
O	110	122	chemotherapy
O	123	125	in
O	126	132	breast
O	133	139	cancer
O	139	140	:
O	141	142	A
O	143	153	randomized
O	154	164	controlled
O	165	173	clinical
O	174	179	study
O	179	180	.

O	181	187	Breast
O	188	194	cancer
O	195	203	patients
O	204	209	often
O	210	217	benefit
O	218	222	from
O	223	231	adjuvant
O	232	244	chemotherapy
O	244	245	,
O	246	247	a
O	248	256	protocol
O	257	262	whose
O	263	276	effectiveness
O	277	279	is
O	280	291	accompanied
O	292	294	by
O	295	304	disabling
O	305	312	adverse
O	313	320	effects
O	320	321	.

O	322	325	The
O	326	329	aim
O	330	332	of
O	333	337	this
O	338	348	controlled
O	349	357	clinical
O	358	363	study
O	364	367	was
O	368	370	to
O	371	380	determine
O	381	384	the
O	385	391	impact
O	392	394	of
O	395	403	visceral
O	404	414	osteopathy
O	415	417	on
O	418	421	the
O	422	431	incidence
O	432	434	of
O	435	441	nausea
O	441	442	/
O	442	450	vomiting
O	450	451	,
O	452	464	constipation
O	465	468	and
O	469	476	overall
O	477	484	quality
O	485	487	of
O	488	492	life
O	493	494	(
O	494	497	QoL
O	497	498	)
O	499	501	in
O	502	507	women
O	508	516	operated
O	517	520	for
O	521	527	breast
O	528	534	cancer
O	535	538	and
O	539	549	undergoing
O	550	558	adjuvant
O	559	571	chemotherapy
O	572	574	in
O	575	581	Centre
O	582	589	Georges
O	590	594	Fran
O	594	595	ç
O	595	598	ois
O	599	606	Leclerc
O	606	607	,
O	608	612	CGFL
O	612	613	.

B-total-participants	614	620	Ninety
I-total-participants	620	621	-
I-total-participants	621	625	four
B-eligibility	626	631	women
I-eligibility	632	640	operated
I-eligibility	641	644	for
I-eligibility	645	646	a
I-eligibility	647	653	breast
I-eligibility	654	660	cancer
I-eligibility	661	666	stage
I-eligibility	667	668	1
I-eligibility	668	669	-
I-eligibility	669	670	3
I-eligibility	670	671	,
I-eligibility	672	674	in
I-eligibility	675	683	complete
I-eligibility	684	693	resection
I-eligibility	694	697	and
I-eligibility	698	700	to
I-eligibility	701	705	whom
I-eligibility	706	707	a
I-eligibility	708	709	3
I-eligibility	710	713	FEC
I-eligibility	714	717	100
I-eligibility	718	730	chemotherapy
I-eligibility	731	734	was
I-eligibility	735	745	prescribed
O	745	746	,
O	747	751	were
O	752	760	randomly
O	761	770	allocated
O	771	773	to
O	774	786	experimental
O	787	789	or
B-control	790	797	placebo
I-control	798	803	group
O	803	804	.

O	805	817	Experimental
O	818	823	group
O	824	833	underwent
O	834	835	a
O	836	844	visceral
O	845	856	osteopathic
O	857	866	technique
O	867	870	and
O	871	878	placebo
O	879	884	group
O	885	888	was
O	889	898	subjected
O	899	901	to
O	902	903	a
O	904	915	superficial
O	916	928	manipulation
O	929	934	after
O	935	939	each
O	940	952	chemotherapy
O	953	958	cycle
O	958	959	.

O	960	964	Rate
O	965	967	of
O	968	973	grade
O	974	975	≥
O	975	976	1
O	977	983	nausea
O	983	984	/
O	984	992	vomiting
O	993	995	or
O	996	1008	constipation
O	1008	1009	,
O	1010	1012	on
O	1013	1016	the
O	1017	1022	first
O	1023	1024	3
O	1025	1031	cycles
O	1032	1034	of
O	1035	1038	FEC
O	1039	1042	100
O	1042	1043	,
O	1044	1048	were
O	1049	1057	reported
O	1057	1058	.

O	1059	1062	QoL
O	1063	1066	was
O	1067	1076	evaluated
O	1077	1082	using
O	1083	1086	the
O	1087	1092	EORTC
O	1093	1096	QLQ
O	1096	1097	-
O	1097	1100	C30
O	1101	1114	questionnaire
O	1114	1115	.

B-outcome	1116	1120	Rate
I-outcome	1121	1123	of
I-outcome	1124	1130	nausea
I-outcome	1130	1131	/
I-outcome	1131	1139	vomiting
I-outcome	1140	1148	episodes
I-outcome	1149	1151	of
I-outcome	1152	1157	grade
I-outcome	1158	1159	≥
I-outcome	1159	1160	1
O	1161	1164	was
O	1165	1169	high
O	1170	1172	in
O	1173	1177	both
O	1178	1190	experimental
O	1191	1194	and
O	1195	1202	placebo
O	1203	1208	group
O	1208	1209	.

B-outcome	1210	1222	Constipation
I-outcome	1223	1231	episodes
I-outcome	1232	1234	of
I-outcome	1235	1240	grade
I-outcome	1241	1242	≥
I-outcome	1242	1243	1
O	1244	1248	were
O	1249	1253	also
O	1254	1262	frequent
O	1262	1263	.

O	1264	1266	No
O	1267	1278	significant
O	1279	1290	differences
O	1291	1295	were
O	1296	1301	found
O	1302	1309	between
O	1310	1313	the
O	1314	1317	two
O	1318	1324	groups
O	1325	1335	concerning
O	1336	1339	the
B-outcome	1340	1344	rate
I-outcome	1345	1347	of
I-outcome	1348	1354	nausea
I-outcome	1354	1355	/
I-outcome	1355	1363	vomiting
O	1364	1365	(
O	1365	1366	p
O	1367	1368	=
O	1369	1370	0
O	1370	1371	.
O	1371	1374	569
O	1374	1375	)
O	1376	1378	or
B-outcome	1379	1391	constipation
O	1392	1393	(
O	1393	1394	p
O	1395	1396	=
O	1397	1398	0
O	1398	1399	.
O	1399	1402	204
O	1402	1403	)
O	1404	1413	according
O	1414	1416	to
O	1417	1426	clinician
O	1427	1435	reported
O	1436	1440	side
O	1440	1441	-
O	1441	1448	effects
O	1449	1452	but
O	1453	1460	patient
O	1461	1469	reported
O	1470	1476	impact
O	1477	1479	of
O	1480	1492	constipation
O	1493	1496	and
O	1497	1506	diarrhoea
O	1507	1509	on
B-outcome	1510	1517	quality
I-outcome	1518	1520	of
I-outcome	1521	1525	life
O	1526	1529	was
O	1530	1543	significantly
O	1544	1549	lower
O	1550	1552	in
O	1553	1565	experimental
O	1566	1571	group
O	1572	1573	(
O	1573	1574	p
O	1575	1576	=
O	1577	1578	0
O	1578	1579	.
O	1579	1582	036
O	1583	1586	and
O	1587	1588	p
O	1589	1590	=
O	1591	1592	0
O	1592	1593	.
O	1593	1596	038
O	1596	1597	,
O	1598	1610	respectively
O	1610	1611	)
O	1611	1612	.

O	1613	1623	Osteopathy
O	1624	1628	does
O	1629	1632	not
O	1633	1639	reduce
O	1640	1643	the
B-outcome	1644	1653	incidence
I-outcome	1654	1656	of
I-outcome	1657	1663	nausea
I-outcome	1663	1664	/
I-outcome	1664	1672	vomiting
O	1673	1675	in
O	1676	1681	women
O	1682	1690	operated
O	1691	1694	for
O	1695	1701	breast
O	1702	1708	cancer
O	1709	1712	and
O	1713	1723	undergoing
O	1724	1732	adjuvant
O	1733	1745	chemotherapy
O	1745	1746	.

O	1747	1749	In
O	1750	1758	contrast
O	1758	1759	,
O	1760	1767	patient
O	1768	1776	reported
O	1777	1786	digestive
O	1787	1794	quality
O	1795	1797	of
O	1798	1802	life
O	1803	1806	was
O	1807	1820	significantly
O	1821	1832	ameliorated
O	1833	1835	by
O	1836	1846	osteopathy
O	1846	1847	.

O	1848	1862	Clinicaltrials
O	1862	1863	.
O	1863	1866	gov
O	1867	1877	Identifier
O	1877	1878	:
O	1879	1890	NCT02840890
O	1890	1891	.
